Genomic Analyses Across Six Cancer Types Identify Basal-like Breast Cancer As a Unique Molecular Entity

Overview

Journal Sci Rep

Specialty Science

Date 2014 Jan 4

PMID 24384914

Citations 26

Authors

Aleix Prat

Barbara Adamo

Cheng Fan

Vicente Peg

Maria Vidal

Patricia Galvan

Ana Vivancos

Paolo Nuciforo

Hector G Palmer

Shaheenah Dawood

Jordi Rodon

Santiago Ramon Y Cajal

Santiago Ramony Cajal

Josep Maria Del Campo

Enriqueta Felip

Josep Tabernero

Javier Cortes

Affiliations

Soon will be listed here.

Abstract

To improve our understanding of the biological relationships among different types of cancer, we have characterized variation in gene expression patterns in a set of 1,707 samples representing 6 human cancer types (breast, ovarian, brain, colorectal, lung adenocarcinoma and squamous cell lung cancer). In the unified dataset, breast tumors of the Basal-like subtype were found to represent a unique molecular entity as any other cancer type, including the rest of breast tumors, while showing striking similarities with squamous cell lung cancers. Moreover, gene signatures tracking various cancer- and stromal-related biological processes such as proliferation, hypoxia and immune activation were found expressed similarly in different proportions of tumors across the various cancer types. These data suggest that clinical trials focusing on tumors with common profiles and/or biomarker expression rather than their tissue of origin are warranted with a special focus on Basal-like breast cancer and squamous cell lung carcinoma.

Citing Articles

Clinical Significance of SOX10 Expression in Human Pathology.

Bahmad H, Thiravialingam A, Sriganeshan K, Gonzalez J, Alvarez V, Ocejo S Curr Issues Mol Biol. 2023; 45(12):10131-10158.

PMID: 38132479 PMC: 10742133. DOI: 10.3390/cimb45120633.

Heterogeneity of triple negative breast cancer: Current advances in subtyping and treatment implications.

Asleh K, Riaz N, Nielsen T J Exp Clin Cancer Res. 2022; 41(1):265.

PMID: 36050786 PMC: 9434975. DOI: 10.1186/s13046-022-02476-1.

Recent advances of transcriptomics and proteomics in triple-negative breast cancer prognosis assessment.

Li Y, Kong X, Wang Z, Xuan L J Cell Mol Med. 2022; 26(5):1351-1362.

PMID: 35150062 PMC: 8899180. DOI: 10.1111/jcmm.17124.

Production of viable chicken by allogeneic transplantation of primordial germ cells induced from somatic cells.

Zhao R, Zuo Q, Yuan X, Jin K, Jin J, Ding Y Nat Commun. 2021; 12(1):2989.

PMID: 34017000 PMC: 8138025. DOI: 10.1038/s41467-021-23242-5.

Discovery of primary prostate cancer biomarkers using cross cancer learning.

Zhou K, Arslanturk S, Craig D, Heath E, Draghici S Sci Rep. 2021; 11(1):10433.

PMID: 34001952 PMC: 8128891. DOI: 10.1038/s41598-021-89789-x.

References

Bang Y, Van Cutsem E, Feyereislova A, Chung H, Shen L, Sawaki A . Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376(9742):687-97. DOI: 10.1016/S0140-6736(10)61121-X. View

Chaffer C, Weinberg R . Cancer cell of origin: spotlight on luminal progenitors. Cell Stem Cell. 2010; 7(3):271-2. PMC: 2941878. DOI: 10.1016/j.stem.2010.08.008. View

Verhaak R, Hoadley K, Purdom E, Wang V, Qi Y, Wilkerson M . Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010; 17(1):98-110. PMC: 2818769. DOI: 10.1016/j.ccr.2009.12.020. View

Anagnostou V, Dimou A, Botsis T, Killiam E, Gustavson M, Homer R . Molecular classification of nonsmall cell lung cancer using a 4-protein quantitative assay. Cancer. 2011; 118(6):1607-18. DOI: 10.1002/cncr.26450. View

Parker J, Mullins M, Cheang M, Leung S, Voduc D, Vickery T . Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009; 27(8):1160-7. PMC: 2667820. DOI: 10.1200/JCO.2008.18.1370. View

Rakha E, Reis-Filho J, Ellis I . Basal-like breast cancer: a critical review. J Clin Oncol. 2008; 26(15):2568-81. DOI: 10.1200/JCO.2007.13.1748. View

Hu Z, Fan C, Livasy C, He X, Oh D, Ewend M . A compact VEGF signature associated with distant metastases and poor outcomes. BMC Med. 2009; 7:9. PMC: 2671523. DOI: 10.1186/1741-7015-7-9. View

Scaltriti M, Eichhorn P, Cortes J, Prudkin L, Aura C, Jimenez J . Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients. Proc Natl Acad Sci U S A. 2011; 108(9):3761-6. PMC: 3048107. DOI: 10.1073/pnas.1014835108. View

Brahmer J, Tykodi S, Chow L, Hwu W, Topalian S, Hwu P . Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012; 366(26):2455-65. PMC: 3563263. DOI: 10.1056/NEJMoa1200694. View

10.

Wilkerson M, Hayes D . ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics. 2010; 26(12):1572-3. PMC: 2881355. DOI: 10.1093/bioinformatics/btq170. View

11.

Saal L, Johansson P, Holm K, Gruvberger-Saal S, She Q, Maurer M . Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci U S A. 2007; 104(18):7564-9. PMC: 1855070. DOI: 10.1073/pnas.0702507104. View

12.

Ellis M, Perou C . The genomic landscape of breast cancer as a therapeutic roadmap. Cancer Discov. 2013; 3(1):27-34. PMC: 3553590. DOI: 10.1158/2159-8290.CD-12-0462. View

13.

Cortes J, Calvo E, Vivancos A, Perez-Garcia J, Recio J, Seoane J . New approach to cancer therapy based on a molecularly defined cancer classification. CA Cancer J Clin. 2013; 64(1):70-4. DOI: 10.3322/caac.21211. View

14.

. Integrated genomic analyses of ovarian carcinoma. Nature. 2011; 474(7353):609-15. PMC: 3163504. DOI: 10.1038/nature10166. View

15.

Kan Z, Jaiswal B, Stinson J, Janakiraman V, Bhatt D, Stern H . Diverse somatic mutation patterns and pathway alterations in human cancers. Nature. 2010; 466(7308):869-73. DOI: 10.1038/nature09208. View

16.

Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D . Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature. 2012; 483(7387):100-3. DOI: 10.1038/nature10868. View

17.

. Comprehensive molecular portraits of human breast tumours. Nature. 2012; 490(7418):61-70. PMC: 3465532. DOI: 10.1038/nature11412. View

18.

Liu X, Holstege H, van der Gulden H, Treur-Mulder M, Zevenhoven J, Velds A . Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. Proc Natl Acad Sci U S A. 2007; 104(29):12111-6. PMC: 1924557. DOI: 10.1073/pnas.0702969104. View

19.

Prat A, Parker J, Karginova O, Fan C, Livasy C, Herschkowitz J . Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 2010; 12(5):R68. PMC: 3096954. DOI: 10.1186/bcr2635. View

20.

Molyneux G, Geyer F, Magnay F, McCarthy A, Kendrick H, Natrajan R . BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell Stem Cell. 2010; 7(3):403-17. DOI: 10.1016/j.stem.2010.07.010. View